马耳他 - 英文 - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol - pressurised inhalation, suspension - salmeterol 25 µg - drugs for obstructive airway diseases

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - salmeterol xinafoate - inhalation powder - 50microgram/1dose

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

pco manufacturing - salmeterol xinafoate - pressurised inhalation suspension - 25 mcg/acutuation - selective beta-2-adrenoreceptor agonists

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - salmeterol - pressurised inhalation, suspension - selective beta-2-adrenoreceptor agonists; salmeterol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - salmeterol - pressurised inhalation, suspension - salmeterol

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - salmeterol as xinafoate - suspension for inhalation - salmeterol as xinafoate 25 mcg/actuation - salmeterol - asthma:serevent is indicated for the regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. serevent is also indicated in the prevention of exercise-induced asthma.chronic obstructive pulmonary disease (copd):serevent is indicated in the treatment of patients with copd.

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - salmeterol as xinafoate - powder for inhalation - salmeterol as xinafoate 50 mcg - salmeterol - salmeterol - salmeterol is a selective beta-2-agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (copd).in asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate -